文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

BHH10治疗绝经后骨质疏松的II期临床试验方案

The efficacy and safety of herbal medicine BHH10 in postmenopausal women with osteoporosis: study protocol for a phase II, multicenter, randomized, double-blinded, placebo-controlled clinical trial.
PubMed 文献 · Trials · 2018-09-10

本研究为II期、多中心、随机、双盲、安慰剂对照临床试验,计划纳入168名55岁及以上绝经后骨质疏松女性,随机1:1分配至BHH10组或安慰剂组,每日三次每次两片,治疗12周。主要疗效指标为腰椎L1-4骨密度从基线至12周的变化,同时评估骨转换标志物、肾虚证指数、EQ-5D评分、实验室参数及不良事件。

要点

  • BHH10是传统韩药,本研究为首个评估其治疗绝经后骨质疏松的临床试验。
  • 主要疗效终点为腰椎L1-4骨密度12周变化,次要终点包括骨转换标志物等。
  • 若BHH10优于安慰剂,可为III期临床试验奠定基础。

核心结论

  • BHH10在绝经后骨质疏松女性中的疗效与安全性尚未知,本试验旨在评估。
  • 若显示优于安慰剂,可为III期临床试验提供基础。

研究设计与样本

  • II期、多中心、随机、双盲、安慰剂对照临床试验。
  • 计划纳入168名55岁及以上绝经后骨质疏松女性,从韩国首尔庆熙大学韩医学院针灸科两个中心竞争性招募。
  • 随机1:1分配至BHH10组或安慰剂组,共5次访视。
  • 干预为每日三次每次两片BHH10或安慰剂,持续12周。

关键数值与推荐

  • 主要疗效指标:腰椎L1-4骨密度从基线(访视1)至随机后12周(访视5)的变化。
  • 其他指标:骨转换标志物、肾虚证指数、EQ-5D评分、实验室参数及不良事件的变化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Osteoporosis is becoming more prevalent in aging societies worldwide, and the economic burden attributable to osteoporotic fractures is substantial. The medications presently available to treat osteoporosis have side effects, and the development of safer and more effective treatments is urgently needed. The aim of this study is to evaluate the efficacy and safety of BHH10, a traditional Korean herbal medicine, in the treatment of postmenopausal osteoporosis. METHODS/DESIGN: This is a phase II, multicenter, randomized, double-blinded, placebo-controlled clinical trial and will include 168 postmenopausal women aged 55 years and older with osteoporosis. The participants will be recruited competitively from two sites of the Acupuncture and Moxibustion Department of Kyung Hee University Hospital of Korean Medicine, either Hoegidong or Gangdong in Seoul, Korea. Participants will be assigned randomly to one of two groups, the BHH10 group or the placebo group, in a 1:1 ratio, and will have five scheduled visits. Participants will take two tablets of BHH10 or placebo three times daily for 12 weeks. The primary efficacy outcome is the change in bone mineral density at the lumbar spine (L1-4) between baseline (visit 1) and 12 weeks after randomization (visit 5). Other outcome variables include changes in bone turnover markers, the Deficiency Syndrome of the Kidney Index, EuroQol five-dimension questionnaire score, and laboratory parameters, as well as adverse events. DISCUSSION: To our knowledge, this will be the first clinical trial to assess the efficacy and safety of BHH10 in postmenopausal women with osteoporosis. It is anticipated that the results will contribute to the development of traditional herbal medicines that can be used to treat osteoporosis in postmenopausal women in Korea. If the superiority of BHH10 over placebo is demonstrated, this study could provide the foundation for a phase III clinical trial. The results of the study will be published in a peer-reviewed journal. TRIAL REGISTRATION: Clinical Research Information Service, KCT0001842 . Registered on 14 March 2016.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Cho Y, Lee S, Kim J, et al. The efficacy and safety of herbal medicine BHH10 in postmenopausal women with osteoporosis: study protocol for a phase II, multicenter, randomized, double-blinded, placebo-controlled clinical trial. Trials. 2018. PMID: 30201024. doi:10.1186/s13063-018-2854-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。